SLC12A2 and glioma: Pharmacological inhibition of NKCC1 or genetically suppression of NKCC1 not only significantly abolishes active cell volume regulations in glioma cells [7,8], but also reduces glioma cell migration in transwell apparatus and in xenograft tumor tissues [5-7].